Alice D.
- Country
- France
- Department
- Oncologie Medicale
Research Overview
- Phase III Randomized, Double-Blind Study of Camizestrant and Palbociclib Versus Anastrozole and Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3 Randomized, Double-Blind Study of Tucatinib with Ado-Trastuzumab Emtansine in Unresectable Locally-Advanced or Metastatic HER2-Positive Breast Cancer
Data & Insights
Has run more than one trial at 14 of 112 partner sites.
Specializations
Breast Cancer Specialization
The investigator demonstrates significant expertise in breast cancer treatment, with particular focus on hormone receptor-positive and HER2-status specific cases.
- HER2-Positive Advanced Disease
- Estrogen Receptor-Positive Cancer
- Early-Stage Breast Cancer
Research interests encompass both early-stage and metastatic breast cancer presentations.
Targeted Therapeutic Approaches
The investigator focuses on novel therapeutic combinations and targeted treatment strategies for breast cancer patients.
- Endocrine Therapy Innovation
- Combined Treatment Modalities
- Advanced Treatment Protocols
Expertise includes evaluation of targeted therapies in combination with established treatments.
Clinical Research Focus
Primary research interests center on treatment optimization for various breast cancer subtypes.
- Progressive Disease Management
- Therapeutic Response Assessment
- Advanced Disease Treatment
Specializes in evaluating therapeutic efficacy in different breast cancer presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.